S-5233

   Amend House File 2377, as amended, passed, and reprinted by the House, as follows:
   1.  Page 23, after line 29 by inserting: 
<DIVISION ___
MEDICAL CANNABIDIOL

   Sec. ___.  Section 124E.2, subsection 2, Code 2018, is amended by adding the following new paragraphs:
   NEW PARAGRAPH.  j.  Glaucoma.
   NEW PARAGRAPH.  k.  Ehlers-Danlos syndrome.
   NEW PARAGRAPH.  l.  Post-traumatic stress disorder.
   NEW PARAGRAPH.  m.  Tourette’s syndrome.
   NEW PARAGRAPH.  n.  Muscular dystrophy.
   NEW PARAGRAPH.  o.  Huntington’s disease.
   NEW PARAGRAPH.  p.  Alzheimer’s disease.
   NEW PARAGRAPH.  q.  Complex regional pain syndrome, types I and II.
   NEW PARAGRAPH.  r.  Rheumatoid arthritis.
   NEW PARAGRAPH.  s.  Polyarteritis nodosa.
   NEW PARAGRAPH.  t.  Hepatitis C.
   NEW PARAGRAPH.  u.  Any other chronic or debilitating disease or medical condition or its medical treatment approved by the department pursuant to rule.
   Sec. ___.  Section 124E.2, subsection 6, Code 2018, is amended to read as follows:
   6.  “Medical cannabidiol” means any pharmaceutical grade cannabinoid found in the plant Cannabis sativa L. or Cannabis indica or any other preparation thereof that has a tetrahydrocannabinol level of no more than three percent and that is delivered in a form recommended by the medical cannabidiol board, approved by the board of medicine, and adopted by the department pursuant to rule.
   Sec. ___.  Section 124E.5, subsection 6, Code 2018, is amended by striking the subsection.>
   2.  By renumbering as necessary.

______________________________
THOMAS A. GREENE